315
On 31 October 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 417. The active ingredient is human Interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and non-glycosylated) (inhalation use) for treatment of renal cell carcinoma.